Text Size
271 studies found for:    "Multiple Sclerosis, Relapsing-Remitting"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Active, not recruiting Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Conditions: Relapsing Remitting Multiple Sclerosis;   Autoimmune Diseases;   Immune System Diseases;   Nervous System Diseases;   Autoimmune Diseases of the Nervous System
Intervention: Drug: BAF312
22 Completed Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon-1beta (Betaseron, BAY86-5046)
23 Recruiting Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
Condition: Relapsing-remitting Multiple Sclerosis
Intervention: Drug: Interferon beta-1b
24 Not yet recruiting Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: RHB-104
25 Active, not recruiting A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Glatiramer acetate (GA);   Other: Placebo
26 Completed A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Device: RebiSmart
27 Completed Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions: Drug: Fingolimod;   Drug: Placebo
28 Completed A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients "TIMER" Study
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Natalizumab (Tysabri®)
29 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab
30 Active, not recruiting Safety and Efficacy Extension Study of Daclizumab HYP to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab HYP
31 Active, not recruiting A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab;   Drug: placebo;   Drug: methylprednisolone;   Drug: interferon beta-1a
32 Completed Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
33 Active, not recruiting Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab HYP
34 Completed Tolerability of Rebif® Injection With and Without the Use of Rebiject™ Mini in Relapsing Remitting Multiple Sclerosis Patients
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Device: Rebiject™ Mini;   Procedure: manual injections
35 Active, not recruiting An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
36 Completed BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: BHT-3009 0.5 mg;   Drug: BHT-3009 1.5 mg;   Drug: Placebo
37 Completed Atorvastatin in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: interferon beta treatment to add-on atorvastatin treatment;   Drug: untreated to atorvastatin treatment
38 Active, not recruiting Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Biological: Helminth ova
39 Completed A Study for Patients With Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: dirucotide;   Drug: placebo
40 Completed Safety of RG2077 in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: RG2077 (CTLA4-IgG4m)
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years